The Worldwide Market for Cancer Diagnostics
Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time it has engaged in an exhaustive study on the status of this important diagnostic market. ( ?id=133884&rt=The-Worldwide-Market-for-Cancer-Diagnostics.html" ?id=133884&rt=The-Worldwide-Market-for-Cancer-Diagnostics.html )
The various diagnostic techniques and trends are discussed from the point of view of their present and potential market impact. Therefore, the report does not provide an in depth discussion of the etiology, physiology and clinical manifestations of cancer except where an understanding of these areas is required to understand the impact that new and early diagnostics exert on patient care. Similarly, the report does not describe the technical aspects of the test modalities, for example
All market data is based on factory sales to the end user and not retail pricing or reimbursement payments. For cancer testing, this means that the actual dollar market - that is what manufacturers earn from the sale of their products is undervalued. This is because many of the new tests are offered as test services either by the companies that have developed the tests and/or their partners. Market data is presented in dollar market size for categories of tests, and for specific analytes where possible. Here the dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.
The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and imaging techniques presented in the report are expected to replace the standard of care in 2010, but with healthcare systems' emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.
This report Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:
* Histology/Cytology
* Immunoassays
* Flow Cytometry
* Rapid Tests
* Molecular Assays
* Tissue Arrays
* Circulating Tumor Cells
* Pharmacodiagnostics
To know more and to buy a copy of your report feel free to visit : ?id=133884&rt=The-Worldwide-Market-for-Cancer-Diagnostics.html" ?id=133884&rt=The-Worldwide-Market-for-Cancer-Diagnostics.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website:
Blog:
Follow us on twitter: